Methods We performed a retrospective clinical study, 140 patients with biopsy-proven LN from were analysed. The renal activity and classification were evaluated according to renal pathology. SLE disease activity was scored using the SLE Disease Activity Index (SLEDAI). Adverse outcome was defined by the occurrence of ESRD or death. The correlations between dyslipidemia and both ESRD and mortality were assessed.

Results Mean age of our patients was 34.63±12,7 years old, 83% were females. Class III, IV and V lupus nephritis accounted for 21%, 58.7% and 11.2% The prevalence of dyslipidemia with elevations in total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG) were noted in in our LN patients, ranging from 41% at diagnosis to 59.7% or even higher after 24 months, and statitns were administered in 23% of the patients

After a mean follow-up of 22 months, ESRD occured in 24%, and death in 13% of cases. Moreover, dyslipidemia was significantly associated to both ESRD (p<0.02) and death (p<0.003).

Conclusions Dyslipidemia is a significant comorbidity of LN that severely affects its renal and overall outcome. Its treatment represents a modifiable risk factor; adequate management can decrease its complications in LN patients and therefore improve their overall morbidity and mortality.